A randomized, double-blind, placebo-controlled clinical trial was conducted in Nairobi, Kenya, to compare single-dose ciprofloxacin with a 7-day course of erythromycin for the treatment of chancroid. In all, 208 men and 37 women presenting with genital ulcers clinically compatible with chancroid were enrolled. Ulcer etiology was determined using culture techniques for chancroid, serology for syphilis, and a multiplex polymerase chain reaction for chancroid, syphilis, and herpes simplex virus (HSV). Ulcer etiology was 31% unmixed chancroid, 23% unmixed syphilis, 16% unmixed HSV, 15% mixed etiology, and 15% unknown. For 111 participants with chancroid, cure rates were 92% with ciprofloxacin and 91% with erythromycin. For all study participants, the treatment failure rate was 15%, mostly related to ulcer etiologies of HSV infection or syphilis, and treatment failure was 3 times more frequent in human immunodeficiency virus-infected subjects than in others, mostly owing to HSV infection. Ciprofloxacin is an effective single-dose treatment for chancroid, but current recommendations for empiric therapy of genital ulcers may result in high treatment failure due to HSV infection.
breakdown in epithelial integrity and the presence of CD4 lymphocytes that are attracted to the ulcer site. Effective treatment for GUD and other sexually transmitted diseases (STDs) can reduce the incidence of HIV-1, and this strategy has become a cornerstone of HIV prevention programs in many parts of the world [8, 9] .
Treatment options for chancroid have become increasingly limited because of the development of resistance to several available and affordable antimicrobials. Penicillin is ineffective because of the production of b-lactamase by essentially all strains, and tetracycline resistance is now widespread, which precludes its use [10] . Trimethoprim-sulfamethoxazole was once an effective single-dose therapy, but resistance first reported in Thailand is now widespread [11] [12] [13] . The World Health Organization (WHO) currently recommends a 7-day course of erythromycin as first-line treatment for chancroid [14] . Although efficacious, poor compliance and gastrointestinal intolerance make alternative therapy desirable. Ciprofloxacin may provide a single-dose oral alternative to erythromycin, and, although it is recommended by WHO as well, rigorous clinical evaluation has been lacking, especially in the era of HIV-1 infection [15] [16] [17] . Azithromycin is an effective oral therapy for chancroid and other STD pathogens, but its high cost and limited availability make it less suitable in resource-poor set- tings [18, 19] . Ceftriaxone 250 mg is another alternative therapy, but it must be given parenterally and may perform less well in HIV-1-positive persons [20, 21] .
The control and potential eradication of chancroid will require more than just adequate treatment. Establishing an accurate etiologic diagnosis of GUD is difficult because of atypical ulcer characteristics, mixed infections, and low sensitivity of available diagnostic tests [22, 23] . In response to these diagnostic limitations, clinical algorithms have been developed that do not require laboratory facilities and use empiric therapy. According to WHO algorithms, empiric treatment for GUD should include specific coverage for chancroid and syphilis and symptomatic therapy for the vesicular lesions of herpes simplex virus (HSV) type 2 [14] . Recent diagnostic advances using nucleic acid amplification technologies have provided an opportunity to identify the etiology of genital ulcers with greater sensitivity and to better understand the epidemiology of GUD [24, 25] .
In this study we evaluated the efficacy and safety of two WHO-recommended treatment regimens for chancroid treatment, identified ulcer-causing pathogens that may mimic or coinfect chancroid ulcers, and evaluated the effect of HIV-1 infection on treatment response.
Methods
Study population. The study was conducted between July 1995 and June 1997 at an urban STD clinic in Nairobi, Kenya. This clinic is designated as a referral center for peripheral health clinics, although 180% of the study participants were self-referred. Men and women between the ages of 18 and 60 who presented with genital ulcers were eligible for enrollment.
Study design. This randomized, placebo-controlled, doubleblind study compared 500 mg of ciprofloxacin as a single dose with 500 mg of erythromycin every 8 h for 7 days. An experienced clinical officer screened all new patients for GUD and referred them to a research clinic for possible enrollment. Only patients with purulent ulcers assessed to be clinically compatible with chancroid were enrolled. In addition, all participants had to be у18 years of age and willing to return to the clinic for follow-up. After determining eligibility, a formal explanation of the study protocol was provided to each participant that included pretest counseling for HIV testing. After a study nurse conducted a structured interview to collect sexual history and demographic information, a blood specimen was collected for HIV and syphilis serology. The study physician then conducted a physical examination that included a detailed genital examination. Information on the number, size, and tenderness of ulcers and associated inguinal lymphadenopathy or bubo formation was recorded. Specimens from the ulcer base were collected for H. ducreyi culture and for H. ducreyi, Treponema pallidum, and HSV polymerase chain reaction (PCR). Medications were then dispensed using coded envelopes, with the first dose of medication taken under direct supervision. Identical packages of medication were provided to each participant. Thus, each participant received either 500 mg of active ciprofloxacin with a 7-day course of erythromycin placebo, to be taken 3 times/day for 7 days, or ciprofloxacin placebo with a 7-day course of 500 mg of active erythromycin to be taken 3 times/day for 7 days.
The response to treatment was evaluated at each follow-up visit by use of an objective assessment grid based on number of ulcers, size of largest ulcer, and tenderness. Ulcers were designated as clinically cured, improved, not improved, or worsened. Buboes, if present, were evaluated by the same scoring system. Weekly followup visits were arranged until complete epithelialization of the ulcers had occurred or the participant was designated as having failed treatment, in which case rescue treatment was prescribed (without breaking the randomization code). The rescue treatment consisted of a 7-day course of erythromycin or single-dose ciprofloxacin in a crossover fashion. Thus, those in whom erythromycin therapy failed would be given ciprofloxacin, and vice versa, but still in a (20) 28 (27) 2 (12) 4 (20) HSV only 11 (11) 14 (13) 5 (29) 8 (40) H. ducreyi ϩ T. pallidum 13 (13) 14 (13) 
14 (13) 17 (16) 3 (18) 2 ( double-blind fashion. The follow-up visits also included a short questionnaire and pill counts. Syphilis serology was available by the first follow-up visit, and intramuscular benzathine penicillin U was provided if indicated. HIV-1 serology was available 6 2.4 ϫ 10 during the first follow-up visit, and a trained counselor conducted posttest counseling.
Laboratory methods.
Specimens from the ulcer base were obtained for H. ducreyi culture by a sterile calcium alginateimpregnated swab and inoculated onto charcoal media. The media consisted of a GC agar base, 1% bovine hemoglobin, 1% isovitalex, 0.2% activated charcoal, and 3 mg/L vancomycin. The plates were collected at the clinic within 4 h and placed in a humidified incubator at 33ЊC with 5% CO 2 for 48 h. H. ducreyi was identified by typical colony morphology and Gram's stain appearance.
Swabs for PCR were collected according to a protocol outlined by Roche Molecular Systems (Alameda, CA). A swab of the ulcer base was taken and vigorously swirled for 15 s in a tube containing sample transport medium supplied by Roche Diagnostic Systems (Branchburg, NJ). The swab was then discarded. The specimen tube was transported to the laboratory in Nairobi within 3 h and frozen at Ϫ80ЊC. About every 3 months these specimen tubes were transported to Winnipeg, Canada, on dry ice where multiplex PCR (M-PCR) was done for the identification of H. ducreyi, T. pallidum, and HSV [26] . Any specimens that showed inhibition of the internal control reaction and were negative for any of the three organisms were extracted with phenol-chloroform and rerun. In instances where the final result was H. ducreyi culture positive but PCR negative, DNA was extracted from the isolate and run in the M-PCR system to ensure that the H. ducreyi primers recognized those particular isolates.
Blood specimens were obtained for syphilis serology and HIV testing. Syphilis seropositivity was determined by the rapid plasma reagin (RPR) test (Macro-Vue RPR card tests; Becton Dickinson, Meylan, France) and confirmed by a T. pallidum hemagglutination test (TPHA test kits; Biotec Laboratories, Ipswich, UK). HIV was determined by EIA (Detect HIV 1/2; BioChem ImmunoSystems, Montreal) and confirmed by a second EIA (Recombigen HIV 1/2; Cambridge BioTech, Galway, Ireland).
Statistical methods. Data analysis was done with SPSS for Windows (SPSS, Chicago). Mean values were compared by Student's t test. Categorical data were analyzed by x 2 and Fisher's exact tests. In univariate analysis, risk ratios and 95% confidence intervals (CIs) were calculated to determine the association between treatment response and a range of demographic and behavioral characteristics. All P values reported are two-tailed.
Results
In total, 208 men and 37 women were enrolled in the study. Table 1 summarizes the demographic and clinical presentations stratified by treatment group. The randomization resulted in ciprofloxacin and erythromycin groups that were well balanced. None of the differences in the characteristics in the table were statistically significant, except that men in the erythromycin group were more likely to have ulcers in the scrotum or pubic area than were men in the ciprofloxacin group ( ). Men P = .02 in the study were older (median age, 27 vs. 24 years;
), P ! .002 more likely to report prior GUD (24% vs. 3%; ), and P ! .003 more likely to report prior nonulcerative sexually transmitted infections (45% vs. 8%, ) than women. Overall, 60% of P ! .001 men reported the likely source of the ulcer to be a casual sexual contact, compared with 24% of women ( ). Although P ! .001 men appeared to have higher risk sexual behaviors, HIV-1 positivity was 31% among men and 62% among women ( ).
The etiologic diagnoses of the genital ulcers are summarized in table 2. Despite attempts to clinically select patients with chancroid, only 48% of men, and 32% of women had H. ducreyi identified from the ulcer and many of these were mixed infections. Overall, the etiology of the ulcers was H. ducreyi alone, 31%; T. pallidum alone, 23%; HSV alone, 16%; and mixed ulcers and no etiology identified, 15% each. Syphilis, both mixed and unmixed infection, was more common in men (40% vs. 22%; ), and HSV was more common in women (38% vs. 17%; P = .04
). Mixed infections accounted for 17% of the ulcers in P = .003 men and 5% of ulcers in women.
Ulcer etiology was strongly associated with HIV-1 infection, as shown in table 3. HIV-1-positive participants were more likely to have HSV identified from the ulcer (36% vs. 11%; ), including a higher rate of unmixed HSV infections P ! .001 (31% vs. 7%;
). This resulted in proportionately more P ! .001 unmixed H. ducreyi infections among the HIV-1-negative group (40% vs. 16%;
). The number of participants without P ! .001 an etiologic diagnosis was higher among the HIV-1-negative participants (19% vs. 8%;
). P ! .02 Table 4 shows a comparison of standard culture methods versus PCR for the detection of H. ducreyi. PCR detected 12 cases that were culture negative but failed to detect 21 culturepositive cases. In order to confirm that the primers were appropriate, DNA was extracted from all culture-positive specimens that were PCR negative. The M-PCR assay was positive in all of these specimens. If the identification of H. ducreyi by culture is considered the reference standard for chancroid diagnosis, the sensitivity of PCR was 79%, and the specificity was 92%. By using a combined reference standard of either culture or PCR positivity, the sensitivity of PCR and culture were 81% and 89%, respectively.
The comparison of syphilis serology with PCR is shown in table 5. In this comparison, PCR identified 20 persons who had negative serology and failed to detect 17 with positive serology. Of the 17 who were not detected by PCR, 13 (76%) had another pathogen identified (11 H. ducreyi positive, 1 HSV positive, and 1 dual infection). It may well be that these persons had prior syphilis infection. However, because of uncertainty as to the best reference standard for syphilis diagnosis, for the purposes of this study, we considered subjects who were positive for syphilis either by PCR or serology (RPR titer у1 : 8 and TPHA positive) to be infected. Other definitions, such as using only PCR results, would not have altered the main study findings. All H. ducreyi isolates were highly sensitive to both erythromycin and ciprofloxacin. The MICs for both antibiotics were р0.06 mg/L of all isolates. Table 6 shows treatment responses for all participants. Of the 120 subjects assigned to the ciprofloxacin group, 106 (88%) returned for у1 follow-up visit; 1 was withdrawn because of an unrelated medical condition. Of the 105 evaluable participants, 20 (19%) did not respond to treatment by day 21. Of the 125 participants assigned to receive erythromycin, 108 (86%) returned for у1 follow-up visit, and treatment failed in 13 (12%). There were no significant differences in the demographic profiles or ulcer etiology between those who returned for follow-up and those who did not. When all participants were included in the analysis, erythromycin appeared to perform better than ciprofloxacin (12% vs. 19% failure rates), although this difference did not reach statistical significance ( ). Of note, of the 20 failures in the ciprofloxacin group, P = .16 the ulcer etiologies were unmixed syphilis, 10; unmixed HSV, 4; mixed syphilis and HSV, 1; undetermined, 1; and chancroid only, 4 (1 unmixed, 3 mixed with syphilis). As ciprofloxacin has no antimicrobial activity against syphilis or HSV, most of the failures were not unexpected. Erythromycin has activity against T. pallidum, and of the 13 failures recorded, the ulcer etiologies were unmixed syphilis, 3; unmixed herpes, 4; undetermined, 2; and unmixed chancroid, 4. Table 7 summarizes the response to treatment among those diagnosed with chancroid by culture or PCR. At least 1 followup visit was recorded for 49 (82%) of 60 participants in the ciprofloxacin group and for 43 (84%) of 51 participants in the erythromycin group. There were 4 clinical failures in each group, although no follow-up H. ducreyi cultures were positive. In the ciprofloxacin group, complete healing of the ulcer occurred by day 7 in 33%, by day 14 in 55%, and by day 21 in 65%. This was very similar to the erythromycin group, in which 33% were healed by day 7, 58% by day 14, and 65% by day 21. There were 13 participants in the ciprofloxacin group and 11 in the erythromycin group who were clinically improved at the last follow-up visit but who did not return for further evaluation. When these improved cases are classified as cured, the overall treatment efficacy of ciprofloxacin was 45 (92%) of 49 and 39 (91%) of 43 for erythromycin. Three of the 4 persons in whom ciprofloxacin treatment failed were coinfected with T. pallidum; in the erythromycin group, treatment failed with 4 unmixed H. ducreyi infections.
Predictors of treatment outcome are shown in table 8. For the analysis that includes all evaluable participants, treatment A blinded rescue treatment was offered to participants in whom initial therapy failed. Erythromycin was used for the 20 participants in whom ciprofloxacin treatment failed, and ciprofloxacin was used for the 13 participants in whom erythromycin treatment failed. Of the 33 persons given rescue treatment, 24 (73%) returned for у1 further follow-up visit. Of these participants, rescue treatment failed in 3. The microbiologic diagnoses in these failures included 2 cases with unmixed syphilis and 1 of unmixed HSV infection; all 3 were HIV-1 positive. Of the 8 chancroid participants who were placed on rescue therapy, only 4 returned for follow-up. All 4 responded to the second course of treatment: 3 received erythromycin, and 1 received ciprofloxacin.
The two treatment regimens were very well tolerated. Six participants reported mild abdominal discomfort from the medication, 5 of whom were taking ciprofloxacin. Of the 108 subjects assigned to receive erythromycin who returned for the day 7 follow-up, only 1 reported mild lower abdominal pain. No person in either group reported discontinuing treatment because of adverse effects.
Discussion
Our results show that 500 mg of ciprofloxacin is a highly effective, well-tolerated, single-dose treatment for chancroid.
Among the 39 participants with documented H. ducreyi infection given ciprofloxacin, only 4 failed to respond to treatment (3 of whom were coinfected with T. pallidum). Erythromycin also performed well in 43 evaluable participants with laboratory-confirmed H. ducreyi infection, although all 4 of the treatment failures occurred in unmixed H. ducreyi infections. Lack of compliance with therapy may explain these failures, although the 4 subjects said they took the medication, and their returned pill packages were empty.
The failure of conventional antimicrobial therapy to adequately treat HIV-1-positive patients has been a concern for chancroid therapy [20, 27] . In this study, HIV-1 infection did not alter the response to treatment in those with H. ducreyi infection but was a significant predictor of treatment failure when all pathogens were included in the analysis. It is evident that the prevalence of both HSV and T. pallidum are higher among HIV-1-positive subjects, and the study was not designed to treat these pathogens.
Ciprofloxacin is characterized by concentration-dependent antimicrobial activity [28] . This means that the higher the plasma/tissue level is above the MIC, the more rapid is the bacterial kill rate. The MIC of ciprofloxacin for all H. ducreyi isolates is very low (generally !0.025 mg/L), and for 24 h after a single 500-mg dose, the concentration of ciprofloxacin will exceed this level by 110-fold [28] . This results in considerable and rapid bacterial killing. On the other hand, ceftriaxone, like other b-lactams, is characterized by concentration-independent antimicrobial activity [29] . Maximum bacterial cell kill is constant and continues for only as long as the plasma drug concentration exceeds the MIC. These pharmacodynamic differences may explain the differences in therapeutic outcome seen with the two single-dose agents. In a previous study [18] , ceftriaxone failed to cure almost one-third of men coinfected with H. ducreyi and HIV. Although HSV testing was not performed in this study and HSV coinfection may therefore have accounted for some treatment failures, 37 (80%) of the 46 clinical failures had H. ducreyi reisolated at follow-up. In the current study, ciprofloxacin cured 80% (8/10) of HIV-positive patients with chancroid, and the 2 persons in whom treatment failed were also both coinfected with T. pallidum. Ceftriaxone, but not ciprofloxacin, may require an intact immune response to "mop up" residual H. ducreyi. The difficulty in making a clinical distinction between chancroid, syphilis, and herpes or a combination of pathogens has been described elsewhere and was confirmed in this study [22] [23] [24] 30] . Despite attempts to select patients with chancroid, only 45% of study participants had H. ducreyi detected from the ulcer, and 30% of these were mixed infections. This has major implications for the management of GUD in clinic settings and strongly supports the use of clinical algorithms. The usual self-limited course of genital herpes and the prohibitive cost of antiviral therapy may argue against the empiric use of antivirals for all genital ulcers. However, genital ulcers that do not respond to initial treatment, especially among HIV-1-positive persons, could be considered for antiviral therapy as second-line treatment. The efficacy of antiviral therapy in this situation will require further study before recommendations can be made, but with acyclovir now off patent, access to HSV treatment should be less problematic in the future. Unfortunately, if there is no diagnostic testing or therapy offered, patients may enter a cycle of repeat clinic visits and be given multiple courses of ineffective antimicrobial treatment. This has implications for the promotion of resistance to H. ducreyi and is a misuse of scarce treatment resources. Furthermore, as active herpetic ulcers shed large quantities of HIV [31] , ulcer treatment should reduce HIV infectivity.
The high proportion of GUD caused by HSV infection among populations with high HIV-1 rates has been described elsewhere. In Tanzania, the seroprevalence of HSV-2 was found to be 75% in women у25 years old and 60% among men aged у30 years [32] . Reliable HSV testing in genital ulcer studies has not been widely used in the past, but in recent studies from Lesotho, Thailand, and India, the prevalences of HSV infection among GUD patients were 25%, 81%, and 23%, respectively [24, 33, 34] .
The development and availability of highly sensitive diagnostic testing for GUD has a profound impact on the ability to study the epidemiology of these infections. The PCR test that was used to detect chancroid performed reasonably well when compared with H. ducreyi culture, although the falsenegative rate was unexpectedly high. There are several possible explanations for this. Culture specimens were always collected first, so it is possible there was insufficient or inadequate material remaining for the PCR swab. In addition, problems with specimen collection, storage, or shipping conditions could have resulted in reduced sensitivity. The presence of inhibitors or difficulty in detecting H. ducreyi DNA in mixed infections are other possible explanations [35] . Further work is required to explore these potential obstacles and to improve test sensitivity. The syphilis PCR did not correlate very closely with serology and highlights the difficulties in interpreting syphilis serology [36] . Previous syphilis infections, treated or untreated, could result in false-positive serology in both nontreponemal and treponemal tests. In addition, a proportion of persons with primary syphilis present before antibodies develop. Without a reference standard, it is difficult to interpret the syphilis PCR results, and it is possible that the true prevalence of syphilis was overestimated. Without the use of PCR in this study, only 56% of the ulcers would have had a pathogen-specific diagnosis. Most previous studies have reported a high proportion of genital ulcers without an identified etiology, and these have often been attributed to culture-negative chancroid. It is clear that with highly sensitive diagnostic testing, an etiology can be identified for the majority of genital ulcers.
There are some potential limitations in this study. We experienced a 13% loss to follow-up, and although this rate is quite low for studies involving STD patients in Africa, it may have introduced bias in the interpretation of therapeutic response. Another potential bias is the inclusion of participants in the cure group who were only improved at last follow-up. This could have resulted in overestimating the efficacy of treatment.
In summary, GUD continues to be endemic in many regions of the world, and intensified efforts are urgently needed to reduce its incidence. In resource-poor settings, the promotion of clinical algorithms should be continued because of the difficulty in establishing an etiologic diagnosis. Ciprofloxacin is a highly effective single-dose treatment for chancroid and may be substituted for erythromycin as empiric therapy for genital ulcers. Its ease of administration may make it a preferred choice, particularly if concomitant syphilis coverage is provided in the syndromic management of GUD. In regions with high HIV prevalence, the role of empiric antiviral therapy for HSV in the management of GUD syndrome merits further study.
